FDA Guidance on Biosimilars Paves Way for New, Multi-billion Dollar Market
This week in healthcare, the FDA releases a guide on biosimilars and at Mayo Clinic measles put cancer into “complete remission”.
This week the FDA released a long-awaited draft guidance sheds light on the measures it will use to evaluate “demonstration of biosimilarity to a reference product.” Read the full draft linked above, or you can read our summary about the impact of this guidance.
In a historic moment for experimental cancer treatment, a woman with tumors in her bone marrow participated in a Mayo Clinic trial where she was injected with a massive dose of a measles vaccine. Her cancer “went into complete remission and was undetectable in Erholtz’s body after just one dose of the measles vaccine, which has an uncanny affinity for certain kinds of tumors.”
This month Massachusetts announced that it would abandon their existing state exchange. To help fix their enrollment process, they will both purchase new software to build a new system and prepare to join the federal exchange in November in case their software is not functioning in time.
Cartoonist Matt Freedman had a unique and creative response to his treatment for tongue and lymph node tumors: he wrote a graphic novel. About his sometime-hilarious, sometimes-bleak chronicle, Relatively Indolent But Relentless: A Cancer Treatment Journal, Freedman said, “I’m amazed at how desperate I felt and all the more grateful I kept the journal.”
Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.